PDUFA V Could Jeopardize U.S. Lead Over EU in Cancer Drug Approvals, Expert Says

International Pharmaceutical Regulatory Monitor
A A
A new study shows the U.S. outpaces Europe in approving new cancer drugs, but that lead could be in jeopardy under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), an expert tells IPRM.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00